|
VOLUME 2, ISSUE
3 (.50 CME credit hours); Release: 6/17/08;
Expiration: 6/17/09
Data in Context: Data Related to HIV Drug Resistance and
Management of Treatment-Experienced Patients from two 2008
Conferences (6th EU HIV Drug Resistance Workshop
and CROI)
In recent months the United States FDA has approved three
new antiretrovirals, maraviroc, raltegravir and etravirine,
for use in treatment-experienced HIV-positive patients who
require a change of therapy in order to suppress viral
replication.
This issue of ResistanceWATCH News©
is designed to provide physicians and other healthcare
providers with important information on best practices in
assessing drug resistance and the management of treatment
experienced patients with recent data from the 6th
HIV Drug Resistance Workshop and CROI 2008.
Read more…
VOLUME 2, ISSUE 2 (.75 CME credit hours); Release: 4/8/08;
Expiration: 4/8/09
Improving Patient-Provider Communication: Addressing the
Complex Issue of Discussing Resistance, Resistance Testing,
and Adherence With Patients
Communicating with patients about the basics of resistance
and the need for resistance testing is complex and daunting,
but such communications are important. This issue of
ResistanceWATCH News©
is designed to facilitate a more learned approach to dealing
with this challenge, illustrating both the need for
increased communication as well as strategies for your busy
practice.
Read more…
VOLUME 2, ISSUE 1 (.50 CME credit hours); Release:
2/5/08;
Expiration: 2/5/09
Putting Developments in HIV Resistance Into Context – Where
We Were and Where We’re Going
Combining drug resistance information with patient history
is now well recognized as a valuable tool for guiding the
success of antiretroviral therapy, so much so that this
information is now a routine component of HIV management and
therapeutic decision-making. This issue of
ResistanceWATCH News© illustrates
just how far we have come in our understanding of HIV drug
resistance over the past 26 years by highlighting past and
current knowledge in the field, when
and how to best detect
drug resistance, and how to optimally use resistance
information to guide treatment.
Read more…
VOLUME 1, ISSUE 3 (.50 CME credit hours); Release: 8/20/07;
Expiration: 8/20/08
Agents
in Expanded Access: Key Data from the XVI HIV Drug
Resistance
Workshop
In
this third issue of ResistanceWATCH© News, we focus our
attention on antiretroviral agents available through expanded access
in three drug classes: integrase inhibitors, CCR5 inhibitors, and
the new nonnucleoside reverse transcriptase inhibitors (NNRTIs). As
clinical experience with these
pipeline drugs
has been relatively brief thus far, researchers still have much to
learn about the evolution of resistance to these agents. This issue
of ResistanceWATCH News© highlights key data
presented at the XVI HIV Drug Resistance Workshop held June 12-16,
2007, in Barbados.
Read more…
|
VOLUME 1, ISSUE 1 (.50 CME
credit hours)
Expired: 4/18/08
HIV Resistance in Context: A Historical Perspective Integrating
Highlights from 14th CROI to Support Current HIV Practice
By taking a look at some of the lessons we’ve learned over the past
years in the area of HIV resistance, this introductory issue of
ResistanceWATCH© News assists readers in better
understanding how to apply new and evolving resistance data (with
highlights from CROI 2007) into their clinical practice, thereby
improving patient outcome. Read
more…
VOLUME 1, ISSUE 2 (.50 CME credit
hours
Expired: 6/19/08
“Hold ‘em or Fold ‘em”? Addressing Challenges in the Treatment
of Multi-Drug Resistant HIV
In this second issue of
ResistanceWATCH© News,
we try to tackle the challenging topic of multi-drug resistant (MDR)
patients. Although antiretroviral therapy has drastically improved
the prognosis of HIV infected individuals, it has resulted in
selection of virus resistant to most or all of our
currently-available therapies in some patients. We will try to
highlight some of the key issues relevant to these patients, and
look ahead to new treatment options which may soon improve our
choices.
Read more…
|
|
